BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
What similarly acting projects are still unpartnered?
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
It’s back to school for biotech, with a packed conference schedule.